TY - JOUR
T1 - Intralymphatic immunotherapy of pollen-induced rhinoconjunctivitis: a double-blind placebo-controlled trial.
AU - Hylander, Terese
AU - Larsson, Olivia
AU - Westin, Ulla
AU - Eriksson, Mia
AU - Kumlien Georén, Susanna
AU - Winqvist, Ola
AU - Cardell, Lars-Olaf
PY - 2016
Y1 - 2016
N2 - Allergen-specific immunotherapy represents the only disease-modifying treatment for allergic diseases. We and others have previously demonstrated that intralymphatic immunotherapy (ILIT), a less time-consuming alternative to conventional subcutaneous immunotherapy (SCIT), is safe and effective. However, this has recently been disputed. The aim of this study was therefore to expand our previous trial, further assessing the safety and efficacy of ILIT.
AB - Allergen-specific immunotherapy represents the only disease-modifying treatment for allergic diseases. We and others have previously demonstrated that intralymphatic immunotherapy (ILIT), a less time-consuming alternative to conventional subcutaneous immunotherapy (SCIT), is safe and effective. However, this has recently been disputed. The aim of this study was therefore to expand our previous trial, further assessing the safety and efficacy of ILIT.
U2 - 10.1186/s12931-016-0324-9
DO - 10.1186/s12931-016-0324-9
M3 - Article
C2 - 26817454
SN - 1465-9921
VL - 17
JO - Respiratory Research
JF - Respiratory Research
IS - 1
M1 - 10
ER -